CQN-WA-SPIE
3.6.2021 18:21:06 CEST | Business Wire | Press release
In the bulleted section of the release dated June 2, 2021, all of the references to June should be July.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20210602005138/en/
The updated release reads:
RIT AND SPIE PARTNER ON 2021 PHOTONICS FOR QUANTUM EVENT
The program, now in its third year, focuses on how photonic devices are impacting quantum science, technology, and applications
On 12-16 July, SPIE, the international society for optics and photonics, and Rochester Institute of Technology (RIT), will present the 2021 Photonics for Quantum Digital Forum . Previously an RIT initiative, this year marks a new iteration of this event in the form of a partnership between RIT and SPIE.
The five-day event will include more than 20 speakers from across international industry and research as well as an interactive poster session. Discussions and presentations will focus on quantum topics spanning applications, experiments, quantum photonic integrated circuits, materials, integration between dissimilar material systems, devices, and concepts to support a national quantum foundry.
Invited speakers include Qunnect’s Noel Goddard ; the US Air Force Research Laboratory’s Michael Fanto ; Imperial College London’s Ian A. Walmsley ; Eleni Diamanti of Sorbonne University’s Laboratoire d'Informatique de Paris 6; Laboratoire Matériaux et Phénomènes Quantiques’ Sara Ducci ; the University of Birmingham’s Kai Bongs ; and Anton Zeilinger of the University of Vienna and the Institute for Quantum Optics and Quantum Information of the Austrian Academy of sciences.
The Photonics for Quantum program sessions include:
- 12 July: Networks and Communication
- 13 July: Computing and Simulation
- 14 July: Sensing and Imaging
- 15 July: Components
- 16 July: Special events and panels, including Women in Quantum (in conjunction with the SPIE Women in Optics program), global government initiatives and funding, and workforce and education
“RIT is thrilled to partner with SPIE to present this year’s Photonics for Quantum conference,” said Don Figer , director of RIT’s Future Photon Initiative. “For the past two years, this event has provided an important forum to discuss the latest breakthroughs in quantum science and technology, as well as how to unlock this growing field’s potential. We look forward to expanding the conference by accessing SPIE’s worldwide network.”
“We’re very excited to be partnering with RIT on this growing event,” said SPIE Director of Industry Development Stephen Anderson . “It’s a wonderful opportunity to help showcase the fast-emerging field of quantum technology and the exciting possibilities that exist in it for photonics. With its particular focus on scientific and academic content, covering both fundamental research and in-lab developments, Photonics for Quantum is a terrific complement to the industry-focused SPIE Quantum West and a great addition to the SPIE calendar.”
Registration for Photonics for Quantum is now open. Visit our website for more information and to register for the event .
About RIT
Rochester Institute of Technology is home to leading creators, entrepreneurs, innovators, and researchers. Founded in 1829, RIT enrolls 18,600 students in more than 200 career-oriented and professional programs, making it among the largest private universities in the US. The university is internationally recognized and ranked for academic leadership in business, computing, engineering, imaging science, liberal arts, sustainability, and fine and applied arts. RIT also offers unparalleled support services for deaf and hard-of-hearing students . The cooperative education program is one of the oldest and largest in the nation. Global partnerships include campuses in China, Croatia, Dubai, and Kosovo.
About SPIE
SPIE is the international society for optics and photonics, an educational not-for-profit organization founded in 1955 to advance light-based science, engineering, and technology. The Society serves more than 258,000 constituents from 184 countries, offering conferences and their published proceedings, continuing education, books, journals, and the SPIE Digital Library. In 2020, SPIE provided over $5 million in community support including scholarships and awards, outreach and advocacy programs, travel grants, public policy, and educational resources. www.spie.org .
View source version on businesswire.com: https://www.businesswire.com/news/home/20210602005138/en/
Link:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Incyte Announces New Positive 54-Week Late-Breaking Data for Povorcitinib in Hidradenitis Suppurativa at the 2026 American Academy of Dermatology (AAD) Annual Meeting28.3.2026 20:00:00 CET | Press release
Phase 3 data from the STOP-HS program demonstrate povorcitinib’s substantial and durable clinical efficacy through Week 54 in patients with moderate to severe hidradenitis suppurativa (HS). Through Week 54, clinically meaningful and durable responses were observed across all groups in both STOP-HS1 and STOP-HS2, with up to 71.4% of patients achieving HiSCR50. Improvements in clinical responses across high stringent thresholds were observed, with up to 57% of participants achieving HiSCR75 and up to 29% of participants achieving HiSCR100. Povorcitinib treatment led to consistent reductions across key inflammatory lesion types, with full resolution (ANdT=0) achieved in up to 20% of patients. Additionally, clinically meaningful improvements in quality-of-life measures, including skin pain and fatigue, were observed at Week 54. The overall safety profile of povorcitinib through 54 weeks is consistent with previously reported data, and both doses were well tolerated. Incyte (Nasdaq:INCY) to
Takeda’s Zasocitinib Delivered Rapid and Durable Skin Clearance in a Convenient Once-Daily Pill, Affirming Promise to Reshape Psoriasis Care28.3.2026 20:00:00 CET | Press release
About 70% of patients treated with zasocitinib achieved clear or almost clear skin (sPGA 0/1) at week 16 in Phase 3 plaque psoriasis studies A significantly greater PASI 75 response rate versus placebo was observed as early as week 4 Safety profile consistent with Phase 2b studies with no new safety signals identified Takeda(TSE:4502/NYSE:TAK)today announced new data from the two pivotal Phase 3studies of zasocitinib (TAK-279), a next-generation, highly selective oral tyrosine kinase 2 (TYK2) inhibitor, in adults with moderate-to-severe plaque psoriasis (PsO).1 Presented as a late-breaking abstract at the 2026 American Academy of Dermatology (AAD) Annual Meeting, these data show that convenient once-daily oral zasocitinib demonstrated rapid and durable skin clearance with a safety profile consistent with Phase 2b studies.1,2 “Our goal in psoriasis treatment is clear or almost clear skin, and previously this has been achieved primarily with injectable therapies,” said Melinda Gooderham,
AAD 2026: Late-Breaking Nemolizumab Data Demonstrate Clinically Meaningful Benefits for Children Aged 2 to 11 With Moderate-to-Severe Atopic Dermatitis28.3.2026 16:00:00 CET | Press release
Pharmacokinetics, safety and efficacy clinical study data show that nemolizumab achieved clinically meaningful reductions in skin lesions and itch through Week 16, which were sustained up to a year in children aged 2 to 11 with moderate-to-severe atopic dermatitis1 These findings reinforce the previously established safety and efficacy of nemolizumab in adults and adolescents with moderate-to-severe atopic dermatitis, for which it is approved by multiple global regulatory authorities2,3 Up to 25% of children are affected by atopic dermatitis, and currently there are limited approved treatment options for children living with moderate-to-severe atopic dermatitis4,5 Galderma (SIX: GALD) today announced new phase II data showing that nemolizumab was well tolerated and effective in children (aged 2 to 11 years) with moderate-to-severe atopic dermatitis, with a clinically meaningful and sustained reduction in skin lesions and itch for up to a year.1 Results will be presented in a late-break
Angelalign Technology (6699.HK)Releases 2025 Results: Passion for Clinical Excellence Drives Worldwide Growth27.3.2026 20:56:00 CET | Press release
Angelalign Technology Inc. (6699.HK) (“Angel” or the “Company”) released its financial results for fiscal year 2025. During the reporting period, the Company continued to do well in both the global and China markets. Total case volume was 532,400, which increased 48.1%, revenue was USD 370.3 million, which increased 37.8%, and adjusted net profit was USD 43.8 million, which increased 63.0%. The results were driven by Angel’s passion for clinical excellence and its open and inclusive culture that empowers talented people to work together to meet customer needs, the Company said. Fox Hu, CEO of Angel, stated: “The clear aligner industry is complex and multidisciplinary. It requires top-tier technical and operational talent along with seamless collaboration among professionals from diverse geographies. Angel’s open and inclusive culture attracts professionals who share a passion for clinical excellence and a dedication to bringing outstanding products and services to customers. This melti
Axway Positioned as a Leader in the IDC MarketScape: Worldwide API Management 2026 Vendor Assessment27.3.2026 18:46:00 CET | Press release
Axway, a 74Software company (Euronext: 74SW) and global leader in federated API management and enterprise integration, has been named a Leader in the IDC MarketScape: Worldwide API Management 2026 Vendor Assessment.1 Axway Amplify securely connects, orchestrates, and automates data integration. Organizations in financial services, manufacturing, healthcare, and other industries rely on Amplify to modernize integrations and confidently unlock data to deliver superior digital services faster. The report notes: “The platform benefits from Axway’s long-standing experience in B2B integration, secure file transfer, and legacy connectivity, providing differentiated capabilities for organizations that need to expose and control APIs around core systems that are not cloud-native.”1 This multi-pattern expertise in security, integration, and federated governance — built during the early phases of the API-driven digital transformation — becomes especially critical as enterprises seek to govern dat
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom